Jevtovic D, Ranin J, Brmbolic B, Salemovic D; International Conference on AIDS.

Int Conf AIDS. 1992 Jul 19-24; 8: B137 (abstract no. PoB 3303).

Institute of Infectious and Tropical Diseases, University Clinical Centre, Belgrade, Yugoslavia.

OBJECTIVES: The aim of our study was to evaluate the efficacy and safety of weekly Fansidar in preventing the recurrence of P. carinii pneumonia (PCP) following successful treatment of acute episode. METHODS: Sixteen pts. with PCP cured from the first episode, were included. Six to 10 days after acute treatment was terminated, Fansidar was started at the dose of 1 tablet weekly. Eleven out of 16 pts. started zidovudine (AZT) therapy as well. The follow-up lasted from 14-80 weeks(median 40 weeks) in the AZT + Fansidar group and 18-32 weeks (median 21 weeks) in the group with Fansidar only. Pts. were evaluated monthly for adverse reactions and outcome, including development of new AIDS-defining conditions and length of survival. Stratified Wilcowon runk-sum test was used to analyze comparability of follow-up times and to compare differences between groups in remaining free of new episodes of PCP the Fisher exact test was performed. RESULTS: Fansidar was well tolerated in all 16 pts. and no adverse reactions were observed. Only one patient from the AZT + Fansidar group developed a recurrence of PCP 6 weeks after Fansidar and AZT were started. Four pts. from the AZT + Fansidar group and 2 pts. From the group taking only Fansidar died during follow-up. Non of them died of pneumonia nor of respiratory distress. It is worth to note that non of Fansidar taking pts. developed cerebral toxoplasmosis during the follow up period. There was no statistically significant difference between the lengths of follow-up times and no difference between groups in the prevalence of new episodes of PCP (n = 0.687, Fisher exact test). CONCLUSION: Fansidar was safe and effective in preventing PCP, without the additional effect of AZT therapy.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Drug Combinations
• Humans
• Pneumonia
• Pneumonia, Pneumocystis
• Pyrimethamine
• Sulfadoxine
• Toxoplasmosis, Cerebral
• Zidovudine
• prevention & control
• sulfadoxine-pyrimethamine
• therapy

Other ID:

• 92401036

UI: 102198749

From Meeting Abstracts